SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is trending as the community rallies behind the developer's transparent, hands-on approach to building a long-term project and overcoming liquidity challenges. While some skeptics voice concerns about typical small-cap volatility and the lack of a chart, holders are actively pushing the token across social platforms and DEX aggregators in anticipation of future growth.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors monitor its lead clinical candidate, AVTX-009, with the community actively discussing potential Phase 2 trial readouts and bullish analyst coverage that underscores its long-term upside. Market participants are closely watching the high trading volume and volatility, while simultaneously expressing caution over the companys ongoing capital requirements and historical dependence on successful clinical data.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as community members rally behind its recent integration with the Stellar ecosystem for stablecoin payroll and speculate on upcoming major partnership announcements. Investors are actively discussing the project's utility and long-term potential, leading to a surge in active wallet holders and heightening anticipation for potential developments at industry events.

WorldFinancial

World Financial (WLFI) is experiencing significant volatility and heavy selling pressure as the community reacts to a congressional probe into its foreign investment dealings and potential conflicts of interest. While some traders view the price dip as a high-conviction buying opportunity supported by institutional interest and upcoming product milestones, others are actively debating whether the project is a long-term utility play or a speculative "pump and dump" scheme linked to political figures.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive is generating buzz following its collaboration with Synthetix to build derivatives on Ethereum, fueling optimism among holders regarding potential protocol growth. Community members are actively tracking the token's technical strength and buyback mechanisms as the asset displays steady upward momentum.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

Binance is trending as investors monitor shifting institutional sentiment and ongoing legal developments, while community members actively debate the platform's liquidity, security measures, and the potential impact of broader regulatory clarity in the crypto market.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending after securing a major 10-year, $865 million colocation agreement with Nscale for its NC-1 AI data center, a development the community sees as a long-awaited catalyst to validate the company's business model. Investors are actively discussing the stock's low float, potential for a short squeeze, and the implications of this contract on the company's long-term revenue growth and ability to attract future hyperscale clients.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is currently a major focus for traders as the stock attempts a recovery following a multi-year downtrend, with community sentiment split between those viewing it as a deep-value turnaround play and others concerned about long-term margin pressure from labor costs and losing Amazon volume. Investors are actively monitoring the stock's consolidation around the $100 level, looking for signs that restructuring efforts and cost-cutting can successfully defend the dividend and drive a sustained breakout.

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Personalis Inc. is trending as investors weigh anticipation for upcoming Medicare coverage decisions against volatility driven by recent capital raises and sector-wide sentiment. The community remains focused on the company's long-term potential as a critical player in oncology diagnostics and personalized cancer vaccines, while actively debating the impact of management's communication strategy and the timing of regulatory milestones.

TOSHI

TOSHI is trending as the community debates its potential for a major recovery, with many members actively buying the dip and citing the token's status as a key project on the Base network. While some investors express frustration over price volatility, the conversation is largely driven by long-term holders discussing technical setups, potential exchange listings, and the broader outlook for memecoins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

8,437 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Nilsine Partners LLC

Nilsine Partners LLC purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the...

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 11.2% during the 4th quarter, according to its most recent filing with...

Wealth Enhancement Advisory Services LLC Boosts Stake in Neurocrine Biosciences, Inc. $NBIX

Wealth Enhancement Advisory Services LLC grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 33.1% in the 4th quarter, according to its most recent disclosure...

SG Americas Securities LLC Buys 119,339 Shares of Neurocrine Biosciences, Inc. $NBIX

SG Americas Securities LLC increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 785.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 134,530 shares of the compan...

Nordea Investment Management AB Increases Stake in Neurocrine Biosciences, Inc. $NBIX

Nordea Investment Management AB boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 81.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 27,202 shares of the company's stock after acquiring an additional 12,195 shares...

Assenagon Asset Management S.A. Has $11.35 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX

Assenagon Asset Management S.A. raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 70.4% in the fourth quarter, according to the company in its most recent...

Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings Neurocrine Biosciences Presents First Expert Consensus Recommendations for...

CIBC Private Wealth Group LLC Grows Stock Position in Neurocrine Biosciences, Inc. $NBIX

CIBC Private Wealth Group LLC boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 17,250.0% during the third quarter, according to the company in its most recent...

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP decreased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 47.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,510 shares of the company's st...

Neurocrine Biosciences Maps 2026 Execution, Data-Rich 2027; Ingrezza Guides $2.7B $2.8B

Neurocrine Biosciences (NASDAQ:NBIX) executives used a conference discussion to frame 2026 as a year of execution ahead of what they described as a data-rich 2027 across multiple mid- and late-stage...

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$131.60
Prev Close	$132.56
Open	$130.81
Dividend Yield	0.00%
50-Day Moving Average	$131.92
Beta	0.75
Avg. Volume	994,323.26
PE Ratio	28.19

52-Week High	$160.18
52-Week Low	$84.23
Market Capitalization	$13.21B
EPS (Annual)	$4.67
Price to Book	4.05
Revenue Per Employee	$1.43M

NBIX
Neurocrine Biosciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NBIX News

NBIXNeurocrine Biosciences, Inc.